Influenza H5 subtype recombinant virus based on VSV vector, inactivated vaccine and preparation method of influenza H5 subtype recombinant virus

By constructing a recombinant virus with VSV as a vector, inserting the NA and HA genes of the H5 subtype avian influenza virus strain, and saving it through reverse genetic technology, the problems of immune safety and immunogenicity of VSV vector vaccine were solved, and an inactivated vaccine preparation with efficient expression and immune safety were achieved.

CN119709648APending Publication Date: 2025-03-28ZHEJIAN DIFFERENCE BIOLOGICAL TECH CO LTD +1
0 Cites 0 Cited by

Patent Information

Application Number
CN202411888247.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-20
Publication Date
2025-03-28

AI Technical Summary

Technical Problem

The prior art is difficult to improve the immune safety of the recombinant virus vaccine with VSV vector, and the immunogenicity of the inactivated virus is closely related to the abundance and conformation of the antigen, but no research on the preparation of inactivated vaccines with VSV vector.

Method used

By inserting the NA and HA genes of the H5 subtype avian influenza virus strain into the vesicular stomatitis virus genome that lacks the surface capsule protein gene, a recombinant virus with VSV as a vector was constructed, and rescued by reverse genetic technology, a recombinant virus that can effectively express the NA and HA protein of the H5 subtype avian influenza virus, and an inactivated vaccine was prepared by physical or chemical inactivation methods.

Benefits of technology

The efficient expression and immunogenicity of the recombinant virus are achieved. The inactivated vaccine has good immune safety and immunogenicity, and can induce high levels of hemagglutination inhibitory titers of avian influenza virus with the assistance of specific adjuvants.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses an influenza H5 subtype recombinant virus based on a VSV carrier, an inactivated vaccine and a preparation method of the influenza H5 subtype recombinant virus, and relates to the technical field of research and development of biological vaccines. The genome of the recombinant virus comprises a VSV genome without a surface envelope protein gene, and an NA gene and an HA gene of an H5 subtype avian influenza virus strain; the NA gene and the HA gene are located between an M gene and an L gene of a VSV genome, and the NA gene and the HA gene are connected in series in the 5 '-3' direction. The recombinant virus rescued by the reverse genetic technology can effectively express the NA antigen and the HA antigen of the H5 subtype avian influenza virus. The inactivated vaccine provided by the invention comprises the inactivated recombinant virus and a vaccine adjuvant, the inactivated recombinant virus loses replication ability, the NA protein and HA protein of the inactivated virus can still play an immune role under the assistance of the specific adjuvant, high-level avian influenza virus hemagglutination inhibition titer can be induced to be generated after a mouse is immunized, and the inactivated vaccine can be used for treating avian influenza virus hemagglutination. The method has the advantage of high safety.
Need to check novelty before this filing date? Find Prior Art